| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 31.23 | 0.00 (0.00%) | 20.50 - 31.89 | 163.8 thousand (Below Avg) |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 31.23 |
| Day's Range | -- - -- |
| Market Cap | 11.9B |
| Avg Volume (10 Day) | 5.5M |
| Price/Earnings (Trailing 12 Mo.) | 20.8x |
| Earnings Per Share (Trailing 12 Mo.) | 1.5 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
"Modern Family" Star Julie Bowen Calls on Communities to Raise Their Hand for Anaphylaxis Awareness in Nationwide Competition
PR Newswire - Tuesday 05/21/2013 9:30 AM ET
Federal Appellate Court Rules in Favor of Mylan in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
PR Newswire - Tuesday 05/21/2013 7:30 AM ET
Mylan Launches Generic Tricor® Tablets
PR Newswire - Friday 05/17/2013 7:30 AM ET
Mylan Launches Generic Zomig® Tablets
PR Newswire - Wednesday 05/15/2013 11:40 AM ET
Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
PR Newswire - Friday 05/10/2013 11:12 AM ET
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
PR Newswire - Thursday 05/02/2013 4:05 PM ET
Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
PR Newswire - Tuesday 04/30/2013 3:15 PM ET
Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector
PR Newswire - Thursday 04/25/2013 9:11 AM ET
| MYL | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 8.96% | |
| Net Income Growth (1yr) | 10.63% | |
| Total Debt/Equity | 2.45 | |
| LT Debt/Equity | 2.25 | |
| Earnings Yield | 4.81% | |
| Price/Sales | 1.74 |
| Company | Last | Change |
|---|---|---|
| Actavis Inc | 130.20 | 0.00% |
| Salix Pharmaceuticals Ltd | 59.33 | 0.00% |
| Akorn Inc | 14.83 | 0.00% |
| Momenta Pharmaceuticals Inc | 13.08 | 0.00% |
| Ligand Pharmaceuticals Inc | 27.74 | 0.00% |
Data is delayed by at least 15 min.